Skip to content
  • by
  • News
  • 2 min read

Wall Street Analyst Calls

UBS has reiterated its buy rating on Nvidia and raised its price target to $540 per share. The investment firm remains bullish on the company heading into earnings next week despite the recent pullback in the stock.

Daiwa stands by its buy rating on Disney following the company's earnings report. The diversified media company's earnings continue to impress.

KBW maintains a market perform rating on Berkshire Hathaway after reviewing the company's 13-F. The value of BRK's equity portfolio has declined quarter-to-date.

Deutsche Bank reiterates its buy rating on Palo Alto Networks and is bullish on the company's earnings later this week as the industry moves beyond the pandemic-fueled product cycle.

Morgan Stanley upgrades Pharvaris to overweight, seeing upside optionality for the pharmaceutical company in the on-demand treatment and prophylactic markets.

Wells Fargo reiterates its overweight ratings on JPMorgan, Citigroup, and Bank of America, noting that “peak rates” could benefit bank stocks.

Evercore ISI maintains its outperform rating on ServiceNow and raises its price target. The firm sees generative AI opportunities for the company.

Barclays remains bullish on Walmart heading into earnings, expecting stronger share gains and signs of stabilization in general merchandise.

Bank of America upgrades Hannon Armstrong to buy, citing the Inflation Reduction Act as a positive catalyst for the climate solutions company.

KeyBanc initiates coverage on Oddity with an overweight rating, viewing the Israeli beauty tech platform as a disruptive tech growth story.

Evercore ISI adds Pure Storage to the tactical outperform list ahead of the data storage company's earnings release later this month.

Bank of America downgrades Phillips 66 and Marathon Petroleum to neutral, no longer finding the risk/reward compelling for these refiners.

Morgan Stanley maintains its overweight rating on Ford, with the expectation of a material change in the company's EV strategy.

Bank of America initiates coverage on Turnstone Biologics as a buy, recognizing the company's potential in developing cellular immunotherapy for certain cancers.